HEOR Scientific Director
Anne-Line Couillerot has been HEOR Scientific Director at Cemka since March 2026.
She is responsible for supporting pharmaceutical and medical device companies in developing cost-effectiveness assessments for health authorities, as well as developing health economic, budgetary and organisational impact tools and tools to assist with price negotiations for healthcare products.
Before joining Cemka, Anne-Line spent five years leading an HEOR and Market Access team for France at a consultancy firm. Her role involved supporting clients in preparing and submitting economic evaluations and drafting reimbursement applications across various therapeutic areas (oncology, rare diseases, neurodegenerative diseases, vaccines).
Prior to that, she worked for 14 years as a project manager within the Economic and Public Health Evaluation Department of the Haute Autorité de Santé (HAS). In this role, she helped implement the mandatory economic evaluation for innovative healthcare products, including the drafting of procedural documents, the methodological guide and the guidelines of the CEESP Commission. In these roles, Anne-Line had the opportunity to review numerous dossiers submitted by manufacturers.
Anne-Line holds a degree in statistical engineering, specialising in health economics (ENSAI).
anne-line.couillerot@cemka.fr
